These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10725904)

  • 1. Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents?
    Meinnel T
    Parasitol Today; 2000 Apr; 16(4):165-8. PubMed ID: 10725904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Target points of antiparasitic drugs].
    Boczoń K
    Wiad Parazytol; 1988; 34(4-6):529-43. PubMed ID: 3071915
    [No Abstract]   [Full Text] [Related]  

  • 3. DNA topoisomerases as targets for antiprotozoal therapy.
    Bakshi RP; Shapiro TA
    Mini Rev Med Chem; 2003 Sep; 3(6):597-608. PubMed ID: 12871162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the design of antibiotics targeting peptide deformylase.
    Hao B; Gong W; Rajagopalan PT; Zhou Y; Pei D; Chan MK
    Biochemistry; 1999 Apr; 38(15):4712-9. PubMed ID: 10200158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific hypothesis: a new strategy for the design of anti-protozoal drugs--DNA polymerase as a drug target.
    Biñas M; Johnson AM
    Appl Parasitol; 1994 Sep; 35(3):157-68. PubMed ID: 7951392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DHFR in parasitic protozoa.
    Anderson AC
    Drug Discov Today; 2005 Jan; 10(2):121-8. PubMed ID: 15718161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a human peptide deformylase: implications for antibacterial drug design.
    Nguyen KT; Hu X; Colton C; Chakrabarti R; Zhu MX; Pei D
    Biochemistry; 2003 Aug; 42(33):9952-8. PubMed ID: 12924944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antibacterial activity of peptide deformylase inhibitors.
    Huntington KM; Yi T; Wei Y; Pei D
    Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase.
    Darkin-Rattray SJ; Gurnett AM; Myers RW; Dulski PM; Crumley TM; Allocco JJ; Cannova C; Meinke PT; Colletti SL; Bednarek MA; Singh SB; Goetz MA; Dombrowski AW; Polishook JD; Schmatz DM
    Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13143-7. PubMed ID: 8917558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.
    Giglione C; Pierre M; Meinnel T
    Mol Microbiol; 2000 Jun; 36(6):1197-205. PubMed ID: 10931273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB.
    Margolis P; Hackbarth C; Lopez S; Maniar M; Wang W; Yuan Z; White R; Trias J
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2432-5. PubMed ID: 11502510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YkrB is the main peptide deformylase in Bacillus subtilis, a eubacterium containing two functional peptide deformylases.
    Haas M; Beyer D; Gahlmann R; Freiberg C
    Microbiology (Reading); 2001 Jul; 147(Pt 7):1783-1791. PubMed ID: 11429456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic properties of Escherichia coli peptide deformylase.
    Meinnel T; Blanquet S
    J Bacteriol; 1995 Apr; 177(7):1883-7. PubMed ID: 7896716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide deformylase as an antibacterial drug target: target validation and resistance development.
    Apfel CM; Locher H; Evers S; Takács B; Hubschwerlen C; Pirson W; Page MG; Keck W
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1058-64. PubMed ID: 11257016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-phosphonate derivatives as novel peptide deformylase inhibitors.
    Hu YJ; Rajagopalan PT; Pei D
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2479-82. PubMed ID: 9873565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species.
    Smith KJ; Petit CM; Aubart K; Smyth M; McManus E; Jones J; Fosberry A; Lewis C; Lonetto M; Christensen SB
    Protein Sci; 2003 Feb; 12(2):349-60. PubMed ID: 12538898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toltrazuril effective against a broad spectrum of protozoan parasites.
    Mehlhorn H; Schmahl G; Haberkorn A
    Parasitol Res; 1988; 75(1):64-6. PubMed ID: 3144713
    [No Abstract]   [Full Text] [Related]  

  • 18. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.
    Hammarton TC; Mottram JC; Doerig C
    Prog Cell Cycle Res; 2003; 5():91-101. PubMed ID: 14593704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
    Coombs GH; Goldberg DE; Klemba M; Berry C; Kay J; Mottram JC
    Trends Parasitol; 2001 Nov; 17(11):532-7. PubMed ID: 11872398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxygen-mediated inactivation of peptide deformylase.
    Rajagopalan PT; Pei D
    J Biol Chem; 1998 Aug; 273(35):22305-10. PubMed ID: 9712848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.